The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
EBITDA before special items decreases to €4.08 billion (7.4%)
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Subscribe To Our Newsletter & Stay Updated
